Literature DB >> 25199771

Clinical characteristics and pathogenesis of cerebellar glioblastoma.

Yoshinobu Takahashi1, Keishi Makino1, Hideo Nakamura1, Takuichiro Hide1, Shigetoshi Yano1, Hajime Kamada2, Jun-Ichi Kuratsu1.   

Abstract

Cerebellar glioblastomas (GBMs) are rare, with neither their pathogenesis nor prognosis being completely understood. The present study aimed to clarify the clinical characteristics of cerebellar GBMs by comparison with supratentorial GBMs, focusing particularly on the pathogenesis. The clinical factors between cerebellar (n=10) and supratentorial (n=216) GBMs were compared. Additionally, p53 and epidermal growth factor receptor (EGFR) levels were investigated in six patients by immunostaining as well as the isocitrate dehydrogenase 1 (IDH1) status of five patients by direct sequencing. Eight males and two females participated in the present study, the mean age at diagnosis was 56.6 years and the range 37-75 years. Four patients presented with hydrocephalus and one with brainstem involvement, and two patients were diagnosed with neurofibromatosis type 1. Two patients had previously received radiotherapy, eight patients received postoperative radiotherapy and seven chemotherapy. The mean Karnofsky performance status (KPS) score was lower in patients with cerebellar GBMs compared to those with supratentorial GBM; however, the survival times did not differ between the two groups. All of the cases of six cerebellar GBMs were p53‑positive and EGFR‑negative, as detected by immunostaining, consistent with secondary GBM. However, no IDH1 mutations were detected in any of the five cases of cerebellar GBMs analyzed, indicating that these tumors were not of the secondary type. The KPS score with cerebellar GBMs may be lower due to hydrocephalus, which was ameliorated by surgery but may have impacted the survival rate. It was confirmed that cerebellar GBMs were identical to supratentorial GBMs with respect to its clinical features, with the possible exception of the KPS score. The present study's genetic analyses indicated that cerebellar GBMs may develop via a pathway different from that of either primary or secondary GBM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25199771     DOI: 10.3892/mmr.2014.2549

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

1.  Treatment patterns and outcomes for cerebellar glioblastoma in the concomitant chemoradiation era: A National Cancer database study.

Authors:  Michael Zhang; Richard Li; Erqi L Pollom; Arya Amini; Savita Dandapani; Gordon Li
Journal:  J Clin Neurosci       Date:  2020-11-06       Impact factor: 1.961

2.  Management, functional outcomes and survival in a French multicentric series of 118 adult patients with cerebellar glioblastoma.

Authors:  Luc Bauchet; Jacques Guyotat; Thiébaud Picart; David Meyronet; Johan Pallud; Chloé Dumot; Philippe Metellus; Sonia Zouaoui; Moncef Berhouma; François Ducray
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-05       Impact factor: 4.553

3.  Characteristics of cerebellar glioblastomas in adults.

Authors:  Thiébaud Picart; Marc Barritault; Julien Berthillier; David Meyronet; Alexandre Vasiljevic; Didier Frappaz; Jérôme Honnorat; Emmanuel Jouanneau; Delphine Poncet; François Ducray; Jacques Guyotat
Journal:  J Neurooncol       Date:  2017-12-01       Impact factor: 4.130

Review 4.  IDH mutations may not preclude distant, trans-tentorial spread in gliomas: a case report and review of the literature.

Authors:  Christopher S Hong; Jason K Hsieh; Nancy A Edwards; Abhik Ray-Chaudhury; Kareem A Zaghloul
Journal:  World J Surg Oncol       Date:  2016-02-24       Impact factor: 2.754

5.  A Rare Case of Cerebellar Glioblastoma Mimicking Acute Stroke in an Elderly Patient.

Authors:  Maleeha Zahid; Laura Yapor; Masooma Niazi; Muhammad Adrish; Ahmad Hanif
Journal:  Am J Case Rep       Date:  2020-09-09

6.  Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.

Authors:  Hee Jin Cho; Junfei Zhao; Sang Won Jung; Erik Ladewig; Doo-Sik Kong; Yeon-Lim Suh; Yeri Lee; Donggeon Kim; Sun Hee Ahn; Mykola Bordyuh; Hyun Ju Kang; Jason K Sa; Yun Jee Seo; Sung Tae Kim; Do Hoon Lim; Yun-Sik Dho; Jung-Il Lee; Ho Jun Seol; Jung Won Choi; Woong-Yang Park; Chul-Kee Park; Raul Rabadan; Do-Hyun Nam
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

7.  Characteristics and management of hydrocephalus in adult patients with cerebellar glioblastoma: lessons from a French nationwide series of 118 cases.

Authors:  Luc Bauchet; Jacques Guyotat; Thiébaud Picart; Chloé Dumot; David Meyronet; Johan Pallud; Philippe Metellus; Sonia Zouaoui; François Ducray; Isabelle Pelissou-Guyotat; Moncef Berhouma
Journal:  Neurosurg Rev       Date:  2021-07-01       Impact factor: 3.042

8.  Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities.

Authors:  Annekathrin Reinhardt; Damian Stichel; Daniel Schrimpf; Christian Koelsche; Annika K Wefers; Azadeh Ebrahimi; Philipp Sievers; Kristin Huang; M Belén Casalini; Francisco Fernández-Klett; Abigail Suwala; Michael Weller; Dorothee Gramatzki; Joerg Felsberg; Guido Reifenberger; Albert Becker; Volkmar H Hans; Marco Prinz; Ori Staszewski; Till Acker; Hildegard Dohmen; Christian Hartmann; Werner Paulus; Katharina Heß; Benjamin Brokinkel; Jens Schittenhelm; Rolf Buslei; Martina Deckert; Christian Mawrin; Ekkehard Hewer; Ute Pohl; Zane Jaunmuktane; Sebastian Brandner; Andreas Unterberg; Daniel Hänggi; Michael Platten; Stefan M Pfister; Wolfgang Wick; Christel Herold-Mende; Andrey Korshunov; David E Reuss; Felix Sahm; David T W Jones; David Capper; Andreas von Deimling
Journal:  Acta Neuropathol Commun       Date:  2019-10-28       Impact factor: 7.801

9.  Discernable differences in the genetic and molecular profile of cerebellar glioblastoma.

Authors:  Muhibullah S Tora; D Cory Adamson
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.